{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:15:00Z","timestamp":1790115300105,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Research Found of Health Commission of Sichuan Provincial","award":["21PJ117"],"award-info":[{"award-number":["21PJ117"]}]},{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"crossref","award":["22NSFSC1284"],"award-info":[{"award-number":["22NSFSC1284"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Youth of Sichuan Science and Technology Program","award":["2023NSFSC1896"],"award-info":[{"award-number":["2023NSFSC1896"]}]},{"name":"Key R&D Project of Sichuan Provincial Department of Science and Technology","award":["2022ZYF1927"],"award-info":[{"award-number":["2022ZYF1927"]}]},{"name":"Key R&D Project of Chengdu Science and Technology Bureau","award":["YF05-01792-SN"],"award-info":[{"award-number":["YF05-01792-SN"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to evaluate the prognostic significance of postoperative Creatine Kinase type M and B (CK-MB) to total Creatine Kinase (CK) ratio (CK-MB\/CK) in colorectal cancer (CRC) patients after radical resection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a single-center retrospective cohort analysis. Subjects were stage I-III CRC patients hospitalized in Sichuan Cancer Hospital from January 2017 to May 2021. Patients were divided into abnormal group and normal group according to whether the CK-MB\/CK ratio was abnormal after surgery. Through a comparative analysis of clinical data, laboratory test results, and prognosis differences between the two groups, we aimed to uncover the potential relationship between abnormal CK-MB\u2009&gt;\u2009CK results and CRC patients. To gauge the impact of CK-MB\/CK on overall survival (OS) and disease-free survival (DFS), we employed the multivariable COX regression and LASSO regression analysis. Additionally, Spearman correlation analysis, logistic regression, and receiver-operating characteristic (ROC) curve analysis were conducted to assess the predictive value of the CK-MB\/CK ratio for postoperative liver metastasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Cox regression analysis revealed that the CK-MB\/CK ratio was a stable risk factors for OS (HR\u2009=\u20093.82,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and DFS (HR\u2009=\u20092.31,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). To distinguish hepatic metastases after surgery, the ROC area under the curve of CK-MB\/CK was 0.697 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and the optimal cut-off value determined by the Youden index was 0.347.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Postoperative abnormal CK-MB\/CK ratio predicts worse prognosis in CRC patients after radical resection and serves as a useful biomarker for detecting postoperative liver metastasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-024-12307-5","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T10:02:42Z","timestamp":1714384962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prognostic value of creatine kinase (CK)-MB to total-CK ratio in colorectal cancer patients after curative resection"],"prefix":"10.1186","volume":"24","author":[{"given":"Lubei","family":"Rao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingyao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiji","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiling","family":"Zu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaijiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuya","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaichao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"key":"12307_CR1","doi-asserted-by":"publisher","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018 68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","DOI":"10.3322\/caac.21492"},{"key":"12307_CR2","doi-asserted-by":"publisher","unstructured":"Wang R, Lian J, Wang X, Pang X, Xu B, Tang S, Shao J, Lu H. Survival rate of colorectal cancer in China: a systematic review and meta-analysis. Front Oncol. 2023;13(1033154). https:\/\/doi.org\/10.3389\/fonc.2023.1033154","DOI":"10.3389\/fonc.2023.1033154"},{"key":"12307_CR3","doi-asserted-by":"publisher","unstructured":"Manfredi S, Bouvier AM, Lepage C, Hatem C, Dancourt V, Faivre J. Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. Br J Surg 2006 93(9):1115\u201322. https:\/\/doi.org\/10.1002\/bjs.5349","DOI":"10.1002\/bjs.5349"},{"key":"12307_CR4","doi-asserted-by":"publisher","unstructured":"Ying HQ, Liao YC, Sun F, Peng HX, Cheng XX. The role of Cancer-elicited inflammatory biomarkers in Predicting Early Recurrence within Stage II-III Colorectal Cancer patients after Curable Resection. J Inflamm Res 2021 14:115\u201329. https:\/\/doi.org\/10.2147\/jir.S285129","DOI":"10.2147\/jir.S285129"},{"key":"12307_CR5","doi-asserted-by":"publisher","unstructured":"Riedesser JE, Ebert MP, Betge J. Precision medicine for metastatic colorectal cancer in clinical practice. Ther Adv Med Oncol 2022 14:17588359211072703. https:\/\/doi.org\/10.1177\/17588359211072703","DOI":"10.1177\/17588359211072703"},{"key":"12307_CR6","doi-asserted-by":"publisher","unstructured":"Kudose Y, Shida D, Ahiko Y, Nakamura Y, Sakamoto R, Moritani K, Tsukamoto S, Kanemitsu Y. Evaluation of recurrence risk after curative resection for patients with stage I to III colorectal Cancer using the hazard function: retrospective analysis of a single-institution large cohort. Ann Surg 2022 275(4):727\u201334. https:\/\/doi.org\/10.1097\/sla.0000000000004058","DOI":"10.1097\/sla.0000000000004058"},{"issue":"2","key":"12307_CR7","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jhep.2012.03.012","volume":"57","author":"Y Soroida","year":"2012","unstructured":"Soroida Y, Ohkawa R, Nakagawa H, Satoh Y, Yoshida H, Kinoshita H, Tateishi R, Masuzaki R, Enooku K, Shiina S, Sato T, Obi S, Hoshino T, Nagatomo R, Okubo S, Yokota H, Koike K, Yatomi Y, Ikeda H. Increased activity of serum mitochondrial isoenzyme of creatine kinase in hepatocellular carcinoma patients predominantly with recurrence. J Hepatol. 2012;57(2):330\u20136. https:\/\/doi.org\/10.1016\/j.jhep.2012.03.012","journal-title":"J Hepatol"},{"key":"12307_CR8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/978-981-10-7757-9_13","volume":"87","author":"U Schlattner","year":"2018","unstructured":"Schlattner U, Kay L, Tokarska-Schlattner M. Mitochondrial proteolipid complexes of creatine kinase. Subcell Biochem. 2018;87:365\u2013408. https:\/\/doi.org\/10.1007\/978-981-10-7757-9_13","journal-title":"Subcell Biochem"},{"issue":"2","key":"12307_CR9","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1515\/cclm-2020-0811","volume":"59","author":"L Zhang","year":"2020","unstructured":"Zhang L, Han F, Liu X, Xie C, Tian K, Bi Q, Hao M, Mu X. Macro creatine kinase in an asymptomatic patient: a case report. Clin Chem Lab Med. 2020;59(2):e61\u20134. https:\/\/doi.org\/10.1515\/cclm-2020-0811","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"12307_CR10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.bbadis.2005.09.004","volume":"1762","author":"U Schlattner","year":"2006","unstructured":"Schlattner U, Tokarska-Schlattner M, Wallimann T. Mitochondrial creatine kinase in human health and disease. Biochim Biophys Acta. 2006;1762(2):164\u201380. https:\/\/doi.org\/10.1016\/j.bbadis.2005.09.004","journal-title":"Biochim Biophys Acta"},{"key":"12307_CR11","doi-asserted-by":"publisher","unstructured":"Collinson P, Suvisaari J, Aakre KM, Baum H, Duff CJ, Gruson D, Hammerer-Lercher A, Pulkki K, Stankovic S, Langlois MR, Apple FS, Laitinen P. How well do Laboratories adhere to recommended guidelines for cardiac biomarkers management in Europe? The CArdiac MARker Guideline Uptake in Europe (CAMARGUE) study of the European Federation of Laboratory Medicine Task Group on Cardiac markers. Clin Chem 2021 67(8):1144\u201352. https:\/\/doi.org\/10.1093\/clinchem\/hvab066","DOI":"10.1093\/clinchem\/hvab066"},{"key":"12307_CR12","doi-asserted-by":"publisher","unstructured":"Alvin MD, Jaffe AS, Ziegelstein RC, Trost JC. Eliminating creatine kinase-myocardial Band Testing in suspected Acute Coronary Syndrome: a value-based quality improvement. JAMA Intern Med 2017 177(10):1508\u201312. https:\/\/doi.org\/10.1001\/jamainternmed.2017.3597","DOI":"10.1001\/jamainternmed.2017.3597"},{"key":"12307_CR13","doi-asserted-by":"publisher","unstructured":"Kovar FM, Aldrian S, Endler G, V\u00e9csei V, Hajdu S, Heinz T, Wagner OF. CK\/CK-MB ratio as an indirect predictor for survival in polytraumatized patients. Wien Klin Wochenschr 2012 124(7\u20138):245\u201350. https:\/\/doi.org\/10.1007\/s00508-012-0155-8","DOI":"10.1007\/s00508-012-0155-8"},{"issue":"1","key":"12307_CR14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1159\/000505724","volume":"13","author":"T Ota","year":"2020","unstructured":"Ota T, Hasegawa Y, Murata E, Tanaka N, Fukuoka M. False-positive elevation of CK-MB levels with chest Pain in Lung Adenocarcinoma. Case Rep Oncol. 2020;13(1):100\u20134. https:\/\/doi.org\/10.1159\/000505724","journal-title":"Case Rep Oncol"},{"issue":"3","key":"12307_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1515\/dx-2018-0039","volume":"6","author":"A Eidizadeh","year":"2019","unstructured":"Eidizadeh A, von Ahsen N, Friedewald S, Binder L. Macro-CK type 2 in metastatic prostate cancer. Diagnosis (Berl). 2019;6(3):307\u20139. https:\/\/doi.org\/10.1515\/dx-2018-0039","journal-title":"Diagnosis (Berl)"},{"issue":"2","key":"12307_CR16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/ajcp\/79.2.255","volume":"79","author":"Annesley","year":"1983","unstructured":"Annesley T. M., McKenna B. J. Ectopic creatine kinase MB production in metastatic cancer. Am J Clin Pathol. 1983;79(2):255\u20139. https:\/\/doi.org\/10.1093\/ajcp\/79.2.255","journal-title":"Am J Clin Pathol"},{"issue":"11","key":"12307_CR17","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.2169\/internalmedicine.56.8329","volume":"56","author":"Y Wada","year":"2017","unstructured":"Wada Y, Tanigawa J, Ishizaka N. Macro-CK and CK-BB contributing to Sham CK-MB Elevation. Intern Med. 2017;56(11):1449\u201350. https:\/\/doi.org\/10.2169\/internalmedicine.56.8329","journal-title":"Intern Med"},{"key":"12307_CR18","doi-asserted-by":"publisher","unstructured":"Chang CC, Liou CB, Su MJ, Lee YC, Liang CT, Ho JL, Tsai HW, Yen TH, Chu FY. Creatine kinase (CK)-MB-to-Total-CK ratio: a Laboratory Indicator for Primary Cancer Screening. Asian Pac J Cancer Prev 2015 16(15):6599\u2013603. https:\/\/doi.org\/10.7314\/apjcp.2015.16.15.6599","DOI":"10.7314\/apjcp.2015.16.15.6599"},{"key":"12307_CR19","doi-asserted-by":"publisher","unstructured":"Uranbileg B, Enooku K, Soroida Y, Ohkawa R, Kudo Y, Nakagawa H, Tateishi R, Yoshida H, Shinzawa S, Moriya K, Ohtomo N, Nishikawa T, Inoue Y, Tomiya T, Kojima S, Matsuura T, Koike K, Yatomi Y, Ikeda H. High ubiquitous mitochondrial creatine kinase expression in hepatocellular carcinoma denotes a poor prognosis with highly malignant potential. Int J Cancer 2014 134(9):2189\u201398. https:\/\/doi.org\/10.1002\/ijc.28547","DOI":"10.1002\/ijc.28547"},{"key":"12307_CR20","doi-asserted-by":"publisher","unstructured":"Qian XL, Li YQ, Gu F, Liu FF, Li WD, Zhang XM, Fu L. Overexpression of ubiquitous mitochondrial creatine kinase (uMtCK) accelerates tumor growth by inhibiting apoptosis of breast cancer cells and is associated with a poor prognosis in breast cancer patients. Biochem Biophys Res Commun 2012 427(1):60\u20136. https:\/\/doi.org\/10.1016\/j.bbrc.2012.08.147","DOI":"10.1016\/j.bbrc.2012.08.147"},{"key":"12307_CR21","doi-asserted-by":"publisher","unstructured":"Lin YC, Chen SC, Huang CM, Hu YF, Chen YY, Chang SL, Lo LW, Lin YJ, Chen SA. Clinical features and diagnosis of new malignancy in patients with acute pulmonary embolism and without a history of cancer. J Chin Med Assoc 2020 83(3):245\u201350. https:\/\/doi.org\/10.1097\/jcma.0000000000000259","DOI":"10.1097\/jcma.0000000000000259"},{"key":"12307_CR22","doi-asserted-by":"publisher","unstructured":"McGing PG, Teeling M, McCann A, Kyne F, Carney DN. Non-M CK\u2013a practical measure of creatine kinase isoenzymes in cancer patients. Clin Chim Acta 1990 187(3):309\u201315. https:\/\/doi.org\/10.1016\/0009-8981(90)90116-a","DOI":"10.1016\/0009-8981(90)90116-a"},{"key":"12307_CR23","doi-asserted-by":"publisher","unstructured":"DeFilippis AP, Chapman AR, Mills NL, de Lemos JA, Arbab-Zadeh A, Newby LK, Morrow DA. Assessment and treatment of patients with type 2 myocardial infarction and Acute Nonischemic Myocardial Injury. Circulation 2019 140(20):1661\u201378. https:\/\/doi.org\/10.1161\/circulationaha.119.040631","DOI":"10.1161\/circulationaha.119.040631"},{"key":"12307_CR24","doi-asserted-by":"publisher","unstructured":"Ruetzler K, Smilowitz NR, Berger JS, Devereaux PJ, Maron BA, Newby LK, de Jesus Perez V, Sessler DI, Wijeysundera DN. Diagnosis and management of patients with myocardial Injury after noncardiac surgery: a Scientific Statement from the American Heart Association. Circulation 2021 144(19):e287\u2013305. https:\/\/doi.org\/10.1161\/cir.0000000000001024","DOI":"10.1161\/cir.0000000000001024"},{"key":"12307_CR25","doi-asserted-by":"publisher","unstructured":"Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol 2018 72(18):2231\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2018.08.1038","DOI":"10.1016\/j.jacc.2018.08.1038"},{"key":"12307_CR26","doi-asserted-by":"publisher","unstructured":"Fagerland M. W. t-tests, non-parametric tests, and large studies\u2013a paradox of statistical practice? BMC Med Res Methodol 2012 12:78. https:\/\/doi.org\/10.1186\/1471-2288-12-78","DOI":"10.1186\/1471-2288-12-78"},{"key":"12307_CR27","doi-asserted-by":"publisher","unstructured":"Hajian-Tilaki K. The choice of methods in determining the optimal cut-off value for quantitative diagnostic test evaluation. Stat Methods Med Res 2018 27(8):2374\u201383. https:\/\/doi.org\/10.1177\/0962280216680383","DOI":"10.1177\/0962280216680383"},{"issue":"5","key":"12307_CR28","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/j.1651-2227.2006.00178.x","volume":"96","author":"A Akobeng","year":"2007","unstructured":"Akobeng A. K. understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr. 2007;96(5):644\u20137. https:\/\/doi.org\/10.1111\/j.1651-2227.2006.00178.x","journal-title":"Acta Paediatr"},{"key":"12307_CR29","doi-asserted-by":"publisher","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021 71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660","DOI":"10.3322\/caac.21660"},{"key":"12307_CR30","doi-asserted-by":"publisher","unstructured":"Chen C, Lin X, Lin R, Huang H, Lu F. A high serum creatine kinase (CK)-MB-to-total-CK ratio in patients with pancreatic cancer: a novel application of a traditional marker in predicting malignancy of pancreatic masses? World J Surg Oncol 2023 21(1):13. https:\/\/doi.org\/10.1186\/s12957-023-02903-3","DOI":"10.1186\/s12957-023-02903-3"},{"key":"12307_CR31","doi-asserted-by":"publisher","unstructured":"Fatemi SR, Pourhoseingholi MA, Asadi F, Vahedi M, Pasha S, Alizadeh L, Zali MR. Recurrence and five -year survival in colorectal Cancer patients after surgery. Iran J Cancer Prev 2015 8(4):e3439. https:\/\/doi.org\/10.17795\/ijcp.3439","DOI":"10.17795\/ijcp.3439"},{"key":"12307_CR32","doi-asserted-by":"publisher","unstructured":"Wang D, Yang Y, Jin L, Wang J, Zhao X, Wu G, Zhang J, Kou T, Yao H, Zhang Z. Prognostic models based on postoperative circulating tumor cells can predict poor tumor recurrence-free survival in patients with stage II-III colorectal cancer. J Cancer 2019 10(19):4552\u201363. https:\/\/doi.org\/10.7150\/jca.30512","DOI":"10.7150\/jca.30512"},{"key":"12307_CR33","doi-asserted-by":"publisher","unstructured":"Konishi T, Shimada Y, Hsu M, Jimenez-Rodriguez TL, Cercek R, Yaeger A, Saltz R, Smith L, Nash JJ, Guillem GM, Paty JG, Garcia-Aguilar PB, Gonen J, Weiser M. M. R. Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon cancer outcome. JAMA Oncol 2018 4(3):309\u201315. https:\/\/doi.org\/10.1001\/jamaoncol.2017.4420","DOI":"10.1001\/jamaoncol.2017.4420"},{"key":"12307_CR34","doi-asserted-by":"publisher","unstructured":"Hermunen K, Soveri LM, Boisen MK, Mustonen HK, Dehlendorff C, Haglund CH, Johansen JS, Osterlund P. Postoperative serum CA19-9, YKL-40, CRP and IL-6 in combination with CEA as prognostic markers for recurrence and survival in colorectal cancer. Acta Oncol 2020 59(12):1416\u201323. https:\/\/doi.org\/10.1080\/0284186x.2020.1800086","DOI":"10.1080\/0284186x.2020.1800086"},{"key":"12307_CR35","doi-asserted-by":"publisher","unstructured":"Abe S, Kawai K, Ishihara S, Nozawa H, Hata K, Kiyomatsu T, Tanaka T, Watanabe T. Prognostic impact of carcinoembryonic antigen and carbohydrate antigen 19\u2009\u2013\u20099 in stage IV colorectal cancer patients after R0 resection. J Surg Res 2016 205(2):384\u201392. https:\/\/doi.org\/10.1016\/j.jss.2016.06.078","DOI":"10.1016\/j.jss.2016.06.078"},{"key":"12307_CR36","doi-asserted-by":"publisher","unstructured":"Sonoda H, Yamada T, Matsuda A, Ohta R, Shinji S, Yokoyama Y, Takahashi G, Iwai T, Takeda K, Ueda K, Kuriyama S, Miyasaka T, Yoshida H. Elevated serum carcinoembryonic antigen level after curative surgery is a prognostic biomarker of stage II-III colorectal cancer. Eur J Surg Oncol 2021 47(11):2880\u20137. https:\/\/doi.org\/10.1016\/j.ejso.2021.05.041","DOI":"10.1016\/j.ejso.2021.05.041"},{"key":"12307_CR37","doi-asserted-by":"publisher","unstructured":"Loo JM, Scherl A, Nguyen A, Man FY, Weinberg E, Zeng Z, Saltz L, Paty PB. Tavazoie S. F. Extracellular metabolic energetics can promote cancer progression. Cell 2015 160(3):393\u2013406. https:\/\/doi.org\/10.1016\/j.cell.2014.12.018","DOI":"10.1016\/j.cell.2014.12.018"},{"key":"12307_CR38","doi-asserted-by":"publisher","unstructured":"Cook NR. Quantifying the added value of new biomarkers: how and how not. Diagn Progn Res 2018 2:14. https:\/\/doi.org\/10.1186\/s41512-018-0037-2","DOI":"10.1186\/s41512-018-0037-2"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12307-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12307-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12307-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T10:03:05Z","timestamp":1714384985000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12307-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12307"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12307-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3577620\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,29]]},"assertion":[{"value":"8 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The research related to human use has complied with all the relevant national regulations, institutional policies and follows the tenets of the Helsinki Declaration, and has been approved by the Institutional Ethics Committee of The Sichuan Cancer Hospital. The Institutional Review Board (IRB) of the Sichuan Cancer Hospital approved this retrospective study (IRB code: SCCHEC-02-2022-017). This retrospective study has been approved to waive informed consent by the Institutional Review Board of the Sichuan Cancer Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The study was a retrospective analysis and didn\u2019t require the patient\u2019s informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"543"}}